Understanding and Managing Infantile PHGDH Deficiency: A Case Report

Mayank Nilay1, Rani Manisha1, Dharmendra Kumar Singh2

  • 1Department of Medical Genetics, Post Graduate Institute of Child Health, Noida, Uttar Pradesh, India.

Neurology India
|January 9, 2026
PubMed

Insights

Phosphoglycerate dehydrogenase deficiency, a rare neurometabolic disorder, can be treated with serine and glycine. Early diagnosis and treatment in children with microcephaly and seizures can improve developmental outcomes.

Area of Science:

  • Neurology
  • Metabolic Disorders
  • Genetics

Background:

  • Phosphoglycerate dehydrogenase deficiency is a rare neurometabolic condition.
  • It presents with severe neurological symptoms like microcephaly, developmental delay, and seizures.
  • These symptoms can be mistaken for cerebral palsy.

Purpose of the Study:

  • To report a case of phosphoglycerate dehydrogenase deficiency in a young child.
  • To highlight the importance of considering treatable neurometabolic disorders in patients with cerebral palsy-like symptoms.
  • To demonstrate the efficacy of serine and glycine supplementation.

Main Methods:

  • Clinical case presentation of a 2.5-year-old boy.
  • Genetic testing to identify a pathogenic variant in the PHGDH gene.
  • Biochemical analysis of serine levels and monitoring treatment response.

Main Results:

  • A homozygous variant c.1129G>A in the PHGDH gene was identified.
  • The patient presented with microcephaly, speech delay, seizures, and hyperactivity.
  • Treatment with oral serine and glycine led to seizure control and developmental catch-up.

Conclusions:

  • Phosphoglycerate dehydrogenase deficiency is a treatable cause of severe neurological impairment.
  • Early diagnosis through genetic and biochemical testing is crucial.
  • Prompt treatment with serine and glycine can significantly improve patient outcomes, averting misdiagnosis as cerebral palsy.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
691
Pedigree Analysis01:35

Pedigree Analysis

Overview
88.8K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
240
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
189